Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 206NIH 84INDUSTRY 32NETWORK 27FED 3INDIV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

Proflavine 9pembrolizumab 2Tacrolimus 2Pyridostigmine Bromide 2Prednisone 2Microbial Collagenase 2sargramostim 1plerixafor 1pegfilgrastim 1olaparib 1nilotinib 1macimorelin 1keyhole-limpet hemocyanin 1ethyl pyruvate 1compound W 1blinatumomab 1Watchful Waiting 1Uracil 1Tegafur 1Surgical Procedures, Operative 1Steroids 1Sodium Chloride 1Sirolimus 1Salicylates 1Peptides 1PM 01183 1Mycophenolic Acid 1Monatide (IMS 3015) 1Mifepristone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDIV × sargramostim × Clear all
NCT03695835 2020-07-22

NIRPA

Gary Onik MD

Completed
27 enrolled
GastrointestinalGenitourinaryThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡